Side by side

1. 1.Activates amylin receptors in the area postrema, a brainstem region that signals fullness.
2. 2.Slows gastric emptying, extending the feeling of fullness after eating.
3. 3.Acts on a different receptor from GLP-1 drugs, which is why it is studied as an add-on to semaglutide.
4. 4.The albumin-binding modification stretches its half-life to roughly a week, allowing weekly injection.
5. 5.Its main side effects are nausea and vomiting rather than the reflux typical of GLP-1 medicines.

• Obesity and overweight, with or without type 2 diabetes
• Combination therapy with semaglutide (CagriSema)
• Add-on to insulin in type 2 diabetes
• Weight maintenance after diet-induced loss

• Reduced appetite and energy intake
• Weight loss of roughly 10 percent alone and around 20 percent combined with semaglutide in trials
• Improved glycaemic markers in type 2 diabetes
• Slower gastric emptying

• Nausea and vomiting, worst during dose escalation
• Reduced appetite, diarrhoea, constipation
• Injection-site reactions
• Gallbladder events, as with other weight-loss drugs
• Rare: pancreatitis

Research context only — dosing exists only inside clinical trials: weekly subcutaneous cagrilintide, usually escalated to 2.4–4.5 mg, and in CagriSema 2.4 mg cagrilintide with 2.4 mg semaglutide weekly. Escalation is deliberately slow to limit nausea. Reject any 'syringe unit' figure you see online: it depends entirely on how a particular vial was reconstituted and is not a clinical dose.

Research context only